Document Detail


Differential indication of lipoprotein apheresis during pregnancy.
MedLine Citation:
PMID:  12924613     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Lipoprotein apheresis is an effective treatment for severe disorders of lipid metabolism. It is the only life prolonging therapy for patients with homozygous familial hypercholesterolemia. Changes of lipid metabolism during pregnancy related to changes of hormone concentrations do not cause clinical complications in the majority of cases. However, in particular clinical situations there is the need to offer a therapeutic option. Increasing morbidity and mortality of mother and child due to severe disorders of lipid metabolism have to be prevented. In general, lipid lowering drugs are contraindicated during pregnancy. Therefore, lipoprotein apheresis offers an alternative, which could be used in select cases to treat acute or chronic hyperlipoproteinemia associated with pregnancy. This article summarizes experiences with patients, who became pregnant during chronic lipoprotein apheresis, or who were treated by lipoprotein apheresis because of acute disorders of lipid metabolism during pregnancy. In conclusion, after individual risk benefit analysis for mother and child lipoprotein apheresis can be safely performed during pregnancy.
Authors:
Reinhard Klingel; Britta Göhlen; Andreas Schwarting; Frido Himmelsbach; Richard Straube
Related Documents :
15875633 - Acute fatty liver of pregnancy complicated with disseminated intravascular coagulation ...
12427793 - Prospective study of liver dysfunction in pregnancy in southwest wales.
16105283 - Diversity in the use of pregnancy-related care among ethnic groups in guatemala.
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy     Volume:  7     ISSN:  1744-9979     ISO Abbreviation:  Ther Apher Dial     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-08-19     Completed Date:  2004-02-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101181252     Medline TA:  Ther Apher Dial     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  359-64     Citation Subset:  IM    
Affiliation:
Apheresis Research Institute, Cologne, Germany. afi@apheresis-research.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Blood Component Removal / methods
Cholesterol, LDL / blood*,  metabolism
Female
Follow-Up Studies
Humans
Hyperlipoproteinemia Type II / diagnosis,  therapy*
Lipid Metabolism
Lipoproteins, LDL / blood*,  metabolism
Plasmapheresis / adverse effects,  methods*
Pregnancy
Pregnancy Complications / diagnosis,  therapy*
Pregnancy Outcome
Pregnancy, High-Risk
Risk Assessment
Severity of Illness Index
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cholesterol, LDL; 0/Lipoproteins, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  From membrane differential filtration to lipidfiltration: technological progress in low-density lipo...
Next Document:  Heparin-induced extracorporeal low-density lipoprotein precipitation.